MBOT — Microbot Medical Inc.

Is MBOT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of August 19, 2026

Microbot Medical Inc. (MBOT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $1.47. The rating moved from Neutral to Oversold on August 13, 2026.

See all oversold Healthcare stocks →

AI analysis

Microbot Medical Inc. (MBOT) is a small, early-stage medical-technology company with limited visible revenue and substantial dependence on successful clinical/regulatory progress and near-term financing. The company’s technology presents a differentiated technical opportunity if clinical outcomes and partnerships materialize, but operational runway, dilution risk, low liquidity, and execution uncertainty dominate the near-term outlook. Absent clear near-term positive clinical readouts, meaningful partnership announcements, or improved financing terms, downside volatility and capital-raising dilution remain the primary constraints on equity value.

Key factors

  • Early-stage / limited commercial traction and likely minimal recurring revenue for Microbot Medical Inc. (MBOT), constraining near-term cash generation
  • High cash burn and likely need for near-term financing or dilution to fund development, regulatory activities, or commercialization
  • Clinical and regulatory execution drives value; positive data or approvals would be a material catalyst but are uncertain
  • Narrow market niche for micro-robotic/targeted delivery solutions with potential competitive and adoption barriers from incumbent device and pharma channels
  • Low liquidity and small market capitalization that amplifies share price volatility on news or social media
  • Sector-level tailwinds for diagnostics/biologics manufacturing do not directly offset company-specific execution and financing risks

Risks

  • Failure to raise non-dilutive capital or inability to access capital markets on reasonable terms, leading to substantial dilution or operational curtailment
  • Unfavorable clinical trial results or regulatory setbacks that materially delay or prevent commercialization
  • Competitive displacement by larger device companies, pharma partners, or alternative drug-delivery technologies
  • Manufacturing, supply-chain or quality-control issues that impede scale-up or adoption
  • Legal, IP or reimbursement challenges that limit market access or increase costs
  • Highly volatile market sentiment and low liquidity producing outsized intraday moves unrelated to fundamentals

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MBOT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.